作为化疗干预靶点的病毒蛋白酶。
Viral proteases as targets for chemotherapeutic intervention.
作者信息
Hellen C U, Wimmer E
机构信息
Department of Microbiology, State University of New York, Stony Brook 11794-8621.
出版信息
Curr Opin Biotechnol. 1992 Dec;3(6):643-9. doi: 10.1016/0958-1669(92)90010-g.
Abstract
Many viruses encode proteinases that are essential for infectivity, and are consequently attractive chemotherapeutic targets. The biochemistry and structure of the human immunodeficiency virus proteinase have been characterized extensively, and potent peptide-mimetic inhibitors have been developed. Techniques and strategies used to improve the efficiency of these compounds are likely to be applicable to other viral proteinases.
摘要
许多病毒编码对感染性至关重要的蛋白酶，因此是有吸引力的化疗靶点。人类免疫缺陷病毒蛋白酶的生物化学和结构已得到广泛表征，并且已开发出有效的肽模拟抑制剂。用于提高这些化合物效率的技术和策略可能适用于其他病毒蛋白酶。
相似文献
1
Viral proteases as targets for chemotherapeutic intervention.作为化疗干预靶点的病毒蛋白酶。
Curr Opin Biotechnol. 1992 Dec;3(6):643-9. doi: 10.1016/0958-1669(92)90010-g.
2
Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.含有别苯基去甲他汀作为过渡态模拟物的HIV蛋白酶抑制剂的设计与合成。
Adv Exp Med Biol. 1995;362:413-23. doi: 10.1007/978-1-4615-1871-6_54.
3
Inhibitors of HIV-1 protease.HIV-1蛋白酶抑制剂。
J Enzyme Inhib. 1992;6(1):65-98. doi: 10.3109/14756369209041357.
4
Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.抑制剂与猫免疫缺陷病毒蛋白酶和人类免疫缺陷病毒蛋白酶结合的比较：基于结构的药物设计与耐药性问题。
Biopolymers. 1999;51(1):69-77. doi: 10.1002/(SICI)1097-0282(1999)51:1<69::AID-BIP8>3.0.CO;2-#.
5
Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
J Med Chem. 1996 Jan 5;39(1):96-108. doi: 10.1021/jm950576c.
6
The HIV-1 protease as a therapeutic target for AIDS.
AIDS Res Hum Retroviruses. 1992 Feb;8(2):153-64. doi: 10.1089/aid.1992.8.153.
7
Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.基于对称性的人免疫缺陷病毒蛋白酶拟肽抑制剂的设计。
Methods Enzymol. 1994;241:334-54. doi: 10.1016/0076-6879(94)41072-0.
8
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.一系列含有羟乙基仲胺过渡态类似物的高效HIV-1蛋白酶抑制剂：合成、酶抑制及抗病毒活性
J Med Chem. 1992 Jul 10;35(14):2525-33. doi: 10.1021/jm00092a002.
9
Potent HIV-1 protease inhibitors with antiviral activities in vitro.
Biochem Biophys Res Commun. 1991 Mar 29;175(3):914-9. doi: 10.1016/0006-291x(91)91652-s.
10
Synergistic binding of inhibitors to the protease from HIV type 1.抑制剂与1型人类免疫缺陷病毒蛋白酶的协同结合。
Biochem J. 1996 Apr 1;315 ( Pt 1)(Pt 1):113-7. doi: 10.1042/bj3150113.
引用本文的文献
1
Viral cysteine proteinases.病毒半胱氨酸蛋白酶
Perspect Drug Discov Des. 1996;6(1):64-86. doi: 10.1007/BF02174046.
2
Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors.弹性蛋白酶特异性抑制剂对脊髓灰质炎病毒和鼻病毒2A蛋白酶蛋白水解活性的抑制作用。
J Virol. 1993 Aug;67(8):4688-95. doi: 10.1128/JVI.67.8.4688-4695.1993.
3
Picornavirus inhibitors.小核糖核酸病毒抑制剂
Pharmacol Ther. 1994;64(2):215-90. doi: 10.1016/0163-7258(94)90040-x.
本文引用的文献
1
Active human immunodeficiency virus protease is required for viral infectivity.活跃的人类免疫缺陷病毒蛋白酶是病毒感染性所必需的。
Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90. doi: 10.1073/pnas.85.13.4686.
2
Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.由大肠杆菌产生的HIV蛋白酶对1型人类免疫缺陷病毒（HIV）体外合成的gag前体蛋白进行加工处理。
J Virol. 1988 Nov;62(11):4393-7. doi: 10.1128/JVI.62.11.4393-4397.1988.
3
Poliovirus proteinase 2A induces cleavage of eucaryotic initiation factor 4F polypeptide p220.脊髓灰质炎病毒蛋白酶2A诱导真核起始因子4F多肽p220的裂解。
J Virol. 1987 Sep;61(9):2711-8. doi: 10.1128/JVI.61.9.2711-2718.1987.
4
Proteolytic processing of polyproteins in the replication of RNA viruses.RNA病毒复制过程中多聚蛋白的蛋白水解加工
Biochemistry. 1989 Dec 26;28(26):9881-90. doi: 10.1021/bi00452a001.
5
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.人免疫缺陷病毒1蛋白酶的体外抑制：底物类似物抑制剂的合理设计
Proc Natl Acad Sci U S A. 1989 Dec;86(24):9752-6. doi: 10.1073/pnas.86.24.9752.
6
X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.人类免疫缺陷病毒1型合成蛋白酶与基于底物的羟乙胺抑制剂复合物的X射线晶体学结构
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8805-9. doi: 10.1073/pnas.87.22.8805.
7
Structure-based, C2 symmetric inhibitors of HIV protease.
J Med Chem. 1990 Oct;33(10):2687-9. doi: 10.1021/jm00172a002.
8
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.针对人类免疫缺陷病毒1蛋白酶的非肽类抑制剂的基于结构的设计。
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6644-8. doi: 10.1073/pnas.87.17.6644.
9
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
Science. 1990 Aug 3;249(4968):527-33. doi: 10.1126/science.2200122.
10
Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease.
J Med Chem. 1990 May;33(5):1285-8. doi: 10.1021/jm00167a003.
Zotero 插件